title: Rituximab-induced interstitial lung disease: case report and literature review.
abstract: Rituximab, a chimeric monoclonal antibody against CD20, very rarely causes lung toxicity. Toxicity may present as interstitial lung disease, alveolar hemorrhage and adult respiratory distress syndrome. Sixteen cases of rituximab-induced interstitial lung disease (R-ILD) have been reported. With this case and a review of all other cases reported in the literature, we will try to identify the features of R-ILD, its treatment and why the early diagnosis of this complication is important.
authors: Salah Azaiez Institute, Tunis, Tunisia. aymen.zayen@laposte.net
authors: Aymen
authors: A
authors: Zayen
authors: Henda
authors: H
authors: Rais
authors: Hela
authors: H
authors: Rifi
authors: Mouna
authors: M
authors: Ouarda
authors: Mehdi
authors: M
authors: Afrit
authors: Aziz
authors: A
authors: Cherif
authors: Amel
authors: A
authors: Mezline